Signalpoint

← Full daily brief

Science brief

Mapping Metabolisms and Diverse Genomes

UK researchers resolve a major weight-loss mystery and identify novel disease targets in South Asian populations.

Signalpoint TeamBrief

Science

Cambridge has resolved the industry's biggest weight-loss mystery — mapping how dual-acting drugs target separate brain regions will accelerate more effective obesity therapies with fewer side effects.

BackgroundObesity treatments like Wegovy and Mounjaro target specific metabolic receptors to curb hunger, but clinical trials had shown conflicting results about whether to stimulate or block GIPR. This scientific confusion had complicated the design of next-generation weight-loss molecules.

Points
  1. The study published in Nature Metabolism reveals that GIPR drugs act on two entirely distinct brain regions, resolving a long-standing debate among molecular biologists.
  2. Stimulating the receptor in the brainstem actively suppresses appetite, whereas blocking the same receptor in the hypothalamus removes a local inhibitory signal to enhance satiety.
  3. The findings clarify why competing candidates from Eli Lilly and Amgen both achieve weight loss, offering a clear framework to design highly targeted, side-effect-free treatments.
SourcesUniversity of Cambridge: Scientists solve mystery behind contradictory behaviours of new weight-loss drugs (opens in new tab)

Science

UK researchers are filling a dangerous gap in genetic medicine — mapping South Asian proteomes reveals novel disease targets that European-only databases completely missed.

BackgroundThe vast majority of global genomic databases are derived from individuals of European ancestry, creating massive health inequalities in diagnostics for ethnic minorities. The UK's 'Genes & Health' programme was established to address this bias by analyzing underrepresented populations.

Points
  1. Published in Nature Genetics, the study analyzed blood samples from 1,400 UK volunteers to trace genetic links to protein levels, establishing a baseline for South Asian health studies.
  2. More than half of the discovered genetic associations were previously undocumented, linking 21 distinct blood proteins to 44 chronic conditions and offering a new path for targeted clinical trials.
  3. The researchers uncovered a novel genetic link between the IGLV3-21 protein and Graves' disease, providing an immediate drug target for an autoimmune thyroid condition that disproportionately affects South Asians.
SourcesQueen Mary University of London: New Nature Genetics study unlocks fresh insights into disease biology and future drug discovery (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.